Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Vestn Ross Akad Med Nauk ; (4): 419-27, 2015.
Article in Russian | MEDLINE | ID: mdl-26710524

ABSTRACT

Sanfilippo syndrome (mucopolysaccharidosis type III) is a lysosomal disorder caused by a defect in the catabolism of heparan sulfate. Mucopolysaccharidosis type III is the most common type of all mucopolysaccharidoses. The pathogenic basis of the disease consists of the storage of undegraded substrate in the central nervous system. Progressive cognitive decline resulting in dementia and behavioural abnormalities are the main clinical characteristics of Sanfilippo syndrome. Mucopolysaccharidosis type III may be misdiagnosed as otherforms of developmental delay, attention deficit/hyperactivity disorder and autistic spectrum disorders because of lack of somatic symptoms, presence of mild and atypical forms of the disease. Patients with Sanfilippo syndrome may have comparatively low urinary glycosaminoglycans levels resulting in false negative urinary assay. Definitive diagnosis is made by enzyme assay on leucocytes and cultured fibroblasts. There is currently no effective treatment of mucopolysaccharidosis type III, though ongoing researches of gene, substrate reduction and intrathecal enzyme replacement therapies expect getting curative method to alter devasting damage of central nervous system in near future.


Subject(s)
Genetic Predisposition to Disease , Mucopolysaccharidosis III , Fibroblasts/pathology , Global Health , Humans , Morbidity/trends , Mucopolysaccharidosis III/diagnosis , Mucopolysaccharidosis III/epidemiology , Mucopolysaccharidosis III/genetics
2.
Vestn Ross Akad Med Nauk ; (9-10): 64-9, 2014.
Article in Russian | MEDLINE | ID: mdl-25816645

ABSTRACT

Beckwith-Wiedemann syndrome (BWS) is etiologically connected with genetic/epigenetic growth dysregulation. The supposed localization of this disorder is a short arm of chromosome 11 (11p 15.5). Its prevalence is 1:13 per 700 newborns. West syndrome is an age-dependent epileptic syndrome related to a group of infantile epileptic encephalopathies and characterized by a triad of basic symptoms: series of infantile spasms, psychomotor retardation and severe paroxysmal EEG changes. The incidence of West syndrome is estimated at 1 case per 2,000-4,000 newborns. The article describes a rare clinical case: a combination of BWS with one of the types of infantile epileptic encephalopathies--West syndrome. A detailed analysis of the West syndrome progression in a female patient with BWS is given, the tactics of antiepileptic therapy is analyzed, and its complexity in terms of metabolic disorders caused by the presence of a genetic syndrome in a patient is shown. The results of a long catamnesis are described. The figures are the fragments of native electroencephalograms at the eruptive phase of West syndrome and against the background of a long-term remission. When describing the clinical case in detail, the authors actively discuss the obtained information and available literature data. The article also presents practical guidelines for the early detection of metabolic disorders in patients with infantile epileptic encephalopathies. In addition to anti-epileptic drugs, the authors propose to include a mandatory metabolic correction in the therapy complex for these patients.


Subject(s)
Beckwith-Wiedemann Syndrome/etiology , Epilepsy, Generalized/etiology , Anticonvulsants/therapeutic use , Beckwith-Wiedemann Syndrome/therapy , Child , Clonazepam , Electroencephalography , Epilepsy, Generalized/therapy , Female , Humans , Infant , Magnetic Resonance Imaging , Spasms, Infantile/etiology , Valproic Acid/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL
...